Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eli Lilly and Company (LLY)

Eli Lilly and Company (LLY)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 193,602,064
  • Shares Outstanding, K 958,426
  • Annual Sales, $ 24,540 M
  • Annual Income, $ 6,194 M
  • 60-Month Beta 0.28
  • Price/Sales 7.97
  • Price/Cash Flow 22.81
  • Price/Book 33.52
Trade LLY with:

Options Overview

Details
  • Implied Volatility 40.49%
  • Historical Volatility 21.98%
  • IV Percentile 91%
  • IV Rank 39.18%
  • IV High 65.40% on 03/18/20
  • IV Low 24.44% on 04/29/20
  • Put/Call Vol Ratio 0.19
  • Today's Volume 1,589
  • Volume Avg (30-Day) 7,480
  • Put/Call OI Ratio 0.36
  • Today's Open Interest 83,996
  • Open Int (30-Day) 87,556

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/21
See More
  • Average Estimate 2.18
  • Number of Estimates 3
  • High Estimate 2.33
  • Low Estimate 2.00
  • Prior Year 1.75
  • Growth Rate Est. (year over year) +24.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
197.96 +4.53%
on 02/22/21
209.95 -1.44%
on 03/02/21
+5.15 (+2.55%)
since 02/05/21
3-Month
146.48 +41.26%
on 12/07/20
218.00 -5.08%
on 01/29/21
+58.47 (+39.39%)
since 12/04/20
52-Week
117.06 +76.76%
on 03/23/20
218.00 -5.08%
on 01/29/21
+66.77 (+47.64%)
since 03/05/20

Most Recent Stories

More News
EMA issues advice on Lilly's bamlanivimab (LY-CoV555) alone and administered together with etesevimab (LY-CoV016) for the treatment of confirmed COVID-19 in the European Union

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive scientific...

LLY : 206.92 (+3.18%)
Loxo Oncology at Lilly Announces Publication of Pirtobrutinib (LOXO-305) Phase 1/2 Data in The Lancet

, /PRNewswire/ -- Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), today announced that has data from the pirtobrutinib (previously referred to as LOXO-305)...

LOXO : 234.80 (+0.06%)
LLY : 206.92 (+3.18%)
Eli Lilly & Co Has Returned 39.8% Since SmarTrend Recommendation (LLY)

SmarTrend identified an Uptrend for Eli Lilly & Co (NYSE:LLY) on November 4th, 2020 at $143.45. In approximately 4 months, Eli Lilly & Co has returned 39.80% as of today's recent price of $200.54.

LLY : 206.92 (+3.18%)
Eli Lilly (LLY) Stock Moves -0.72%: What You Should Know

Eli Lilly (LLY) closed the most recent trading day at $200.54, moving -0.72% from the previous trading session.

LLY : 206.92 (+3.18%)
Biotech Stock Roundup: REGN, VIR's COVID-19 Updates, KMPH's Drug Approval & More

The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Vir (VIR) and KemPharm, Inc. (KMPH).

REGN : 461.57 (+2.71%)
SNY : 46.59 (+1.50%)
INCY : 80.26 (+3.56%)
LLY : 206.92 (+3.18%)
KMPH : 10.05 (+4.36%)
ASLN : 3.42 (+3.32%)
VIR : 45.18 (+13.89%)
As SGLT2 Inhibitors Create Increased Market Complexities for Chronic Kidney Disease Non-Dialysis Patients, How Quickly Will Patient Care Evolve - If at All?

, /PRNewswire/ -- Chronic kidney disease (CKD) patients experience a wide range of comorbidities and risks associated with their disease, such as diabetic complications, hyperkalemia, and metabolic acidosis....

LLY : 206.92 (+3.18%)
MRK : 73.13 (+1.33%)
Tirzepatide achieved superior A1C and body weight reductions across all three doses compared to injectable semaglutide in adults with type 2 diabetes

, /PRNewswire/ -- Tirzepatide led to superior A1C and body weight reductions from baseline across all three doses compared to injectable semaglutide 1 mg in adults with type 2 diabetes in Eli Lilly and...

LLY : 206.92 (+3.18%)
Oncology Drugs Market to Exhibit a CAGR of 11.6% and Hit USD 394.24 Billion by 2027; Burgeoning Pharmaceutical Industry to Create Lucrative Opportunities, states Fortune Business Insights(TM)

The global oncology drugs market size is expected to reach USD 394.24 billion by 2027, exhibiting a CAGR of 11.6% during the forecast period. The growing prevalence of cancer around the world will spur...

BAYRY : 15.4550 (+0.10%)
BMY : 60.43 (+1.84%)
LLY : 206.92 (+3.18%)
GSK : 34.91 (+1.84%)
NVS : 84.01 (+0.61%)
PFE : 34.39 (+0.56%)
Autism Spectrum Disorder Therapeutics Market Projected to Hit USD 4,612.1 Million and Surge at 4.3% CAGR by 2026; Awareness Campaigns Conducted to Spread Awareness Regarding the Condition to Propel Growth, Says Fortune Business Insights(TM)

According to a report published by Fortune Business Insights, titled, "Autism Spectrum Disorder Therapeutics Market": Global Market Analysis, Insights and Forecast, 2018-2026," the global market is likely...

AGN : 193.02 (+0.02%)
LLY : 206.92 (+3.18%)
FSNN : 0.0580 (-19.44%)
OTSKY : 20.3100 (+1.80%)
PFE : 34.39 (+0.56%)
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

, /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ:INCY) announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib...

LLY : 206.92 (+3.18%)
INCY : 80.26 (+3.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. They were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and they remain true to that mission in all their...

See More

Key Turning Points

3rd Resistance Point 216.22
2nd Resistance Point 211.95
1st Resistance Point 209.43
Last Price 206.92
1st Support Level 202.64
2nd Support Level 198.37
3rd Support Level 195.85

See More

52-Week High 218.00
Last Price 206.92
Fibonacci 61.8% 179.44
Fibonacci 50% 167.53
Fibonacci 38.2% 155.62
52-Week Low 117.06

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar